financetom
Business
financetom
/
Business
/
Canada's International Trade Deficit Expands as Expected in June, Says BMO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Canada's International Trade Deficit Expands as Expected in June, Says BMO
Aug 5, 2025 6:50 AM

09:22 AM EDT, 08/05/2025 (MT Newswires) -- Canada's merchandise trade deficit was little changed at $5.9 billion in June from a revised $5.5 billion -- previously also $5.9 billion -- in May, said Bank of Montreal (BMO) after Tuesday's data release.

Exports were up 0.9% month over month, led by energy (+3.8%, as higher energy prices helped drive the first increase since January) and farm, fishing, and intermediate food products (+6.7%). Meantime, higher tariffs on steel and aluminum, along with a decline in gold from May's surge, weighed on exports of metal and non-metallic mineral products (-3.4%).

Auto exports fell 4.2%, and are now down 8.5% y/y alongside slower domestic production.

Imports rose 1.4% month over month for their first increase in four months thanks to a one-time shipment in industrial machinery and equipment (+27.7%) destined for an offshore oil project in Newfoundland. Excluding this category, imports were down 1.9%.

In volume terms, exports plunged 31.1% a.r. in Q2 while imports were down 6.1% annualized. Unsurprisingly, BMO expects trade to weigh heavily on growth as trade uncertainty peaked in the second quarter.

Separately, the services trade deficit clocked in at $700 million from $900 million in May. Altogether, Canada's overall trade deficit was little changed at $6.5 billion in June.

Despite the usual volatility, Canada's trade figures came in line with expectations for June. While trade flows have recovered a touch from the spring, normalization is unlikely until the Canada-U.S. relationship stabilizes, added the bank.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Shift4 Payments Launches Global Cryptocurrency Payment Service
Shift4 Payments Launches Global Cryptocurrency Payment Service
Nov 3, 2024
09:42 AM EDT, 10/28/2024 (MT Newswires) -- Shift4 Payments ( FOUR ) said Monday it has launched Pay with Crypto, allowing businesses worldwide to accept cryptocurrency for e-commerce and point-of-sale transactions. The service supports various cryptocurrencies, including Bitcoin, Ethereum, Solana, and US Dollar Coin, and payments will be automatically converted to US dollars for settlement, Shift4 said. The new feature,...
First Northwest Bancorp Says FDIC Terminates Consent Order Against Unit
First Northwest Bancorp Says FDIC Terminates Consent Order Against Unit
Nov 3, 2024
09:43 AM EDT, 10/28/2024 (MT Newswires) -- First Northwest Bancorp's ( FNWB ) First Fed Bank unit said Monday the Federal Deposit Insurance Corp. has terminated the November 2023 consent order issued against the bank. First Fed Bank said it has resolved the deficiencies in its compliance program that was the subject of the FDIC's order. In other news, First...
Organon Finalizes Acquisition of Dermavant From Roivant
Organon Finalizes Acquisition of Dermavant From Roivant
Nov 3, 2024
09:44 AM EDT, 10/28/2024 (MT Newswires) -- Organon (OGN) said Monday it finalized the acquisition of Dermavant Sciences from Roivant (ROIV). Dermavant develops and commercializes treatments in the immuno-dermatology space, including Vtama, which was approved by the US Food and Drug Administration to treat plaque psoriasis in adults, Organon said. Price: 17.37, Change: +0.21, Percent Change: +1.22 ...
Ironwood Says Apraglutide Shows 'Consistent Treatment Effect' in Short Bowel Syndrome; Shares Rise
Ironwood Says Apraglutide Shows 'Consistent Treatment Effect' in Short Bowel Syndrome; Shares Rise
Nov 3, 2024
09:42 AM EDT, 10/28/2024 (MT Newswires) -- Ironwood Pharmaceuticals ( IRWD ) said Monday that data from a phase 3 trial assessing apraglutide in adults with short bowel syndrome with intestinal failure showed a consistent treatment effect. The consistent effect was seen across subgroups: gender, age, body weight, region, race, ethnicity and [short bowel syndrome characteristics] -- including length of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved